nach oben

Medical Oncology

Erschienen in:

01.11.2014 | Original Paper

The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism

verfasst von: Dong Jiang, Yun-yun Xu, Fang Li, Biao Xu, Xue-guang Zhang

Erschienen in: Medical Oncology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the role of co-stimulatory molecule B7-H1 in gastric carcinoma, to assess its clinical significance, and to explore related mechanism. Expression of B7-H1 and interferon gamma (IFN-γ) was evaluated by immunohistochemistry in 205 gastric carcinoma tissues and nonmalignant para-carcinoma tissues and 30 normal tissues. Expression data were correlated with clinicopathologic features of the patients. Furthermore, gastric carcinoma cell line SGC7901, MGC803, and AGS were employed to assess the expression of B7-H1 under the stimulation of IFN-γ. There was no detectable or weak amount of B7-H1 in normal tissue, while 43 % (88/205) of gastric carcinoma tissues and nonmalignant para-carcinoma tissues were confirmed with B7-H1 positive (p < 0.01). High B7-H1 expression was significantly associated with the age (p < 0.01), alcohol (p < 0.05), carcinoma location (p < 0.01), and differentiation (p < 0.05). Moreover, IFN-γ and CD3⁺ T cells infiltration were found in carcinoma tissues, but not in normal tissues. In addition, the expression of B7-H1 was also found in gastric carcinoma cell lines (SGC7901, MGC803 and AGS), and IFN-γ could increase its expression. Our data suggest that B7-H1 may represent a new early diagnostic marker for patients with well-differentiated gastric carcinoma. Furthermore, given its immune-inhibitory function, B7-H1 may represent a potential target in the treatment of gastric carcinoma.

de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219–40. doi:10.1016/j.gtc.2013.01.003.PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Zou XN, Duan JJ, Huangfu XM, Chen WQ, Zhao P. Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China, 2004–2005. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44(5):390–7.PubMed

Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8. doi:10.3748/wjg.v17.i39.4421.PubMedCrossRefPubMedCentral

Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807–39. doi:10.1146/annurev.immunol.21.120601.141135.PubMedCrossRef

Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30(3):251–60. doi:10.1097/CJI.0b013e31802e085a.PubMedCrossRef

Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–26. doi:10.1038/nri727.PubMedCrossRef

Vigano S, Perreau M, Pantaleo G, Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol. 2012;2012:485781. doi:10.1155/2012/485781.PubMedPubMedCentral

Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–9. doi:10.1038/70932.PubMedCrossRef

10.

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10(15):5094–100. doi:10.1158/1078-0432.CCR-04-0428.PubMedCrossRef

11.

Xiao JX, Bai PS, Lai BC, Li L, Zhu J, Wang YL. B7 molecule mRNA expression in colorectal carcinoma. World J Gastroenterol. 2005;11(36):5655–8.PubMed

12.

Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19–24. doi:10.1016/j.acthis.2006.01.003.PubMedCrossRef

13.

Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947–53. doi:10.1158/1078-0432.CCR-04-1469.PubMedCrossRef

14.

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5. doi:10.1158/0008-5472.CAN-05-4303.PubMedCrossRef

15.

Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74. doi:10.1038/85339.PubMedCrossRef

16.

Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8(3):190–8. doi:10.1593/neo.05733.PubMedCrossRefPubMedCentral

17.

Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45. doi:10.1002/ijc.27711.PubMedCrossRef

18.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119(2):317–27. doi:10.1002/ijc.21775.PubMedCrossRef

19.

Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82. doi:10.1007/s00262-006-0266-z.PubMedCrossRef

20.

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–7. doi:10.1158/1078-0432.CCR-06-2746.PubMedCrossRef

21.

Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008;268(1):98–109. doi:10.1016/j.canlet.2008.03.056.PubMedCrossRef

22.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293–7. doi:10.1073/pnas.192461099.PubMedCrossRefPubMedCentral

23.

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm730.PubMed

24.

Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009;100(6):500–4. doi:10.1002/jso.21376.PubMedCrossRef

Titel: The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism
verfasst von: Dong Jiang
Yun-yun Xu
Fang Li
Biao Xu
Xue-guang Zhang
Publikationsdatum: 01.11.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 11/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0268-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients

Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer

Overexpression of enhancer of zeste human homolog 2 (EZH2) gene in human cytomegalovirus positive glioblastoma multiforme tissues

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women

Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer

Uracil-DNA glycosylase (UNG) rs246079 G/A polymorphism is associated with decreased risk of esophageal cancer in a Chinese population

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie